TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21058479
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group of Four Points of Throat acupuncture and routine medication (group 1)
Study: 21058479
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication only (group 2)
Study: 15861018
Drug: omeprazole +
Normalized name: Omeprazole + SyrSpend SF Alka
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole + amoxicillin with metronidazole
Study: 15861018
Drug: omeprazole +
Normalized name: Omeprazole + SyrSpend SF Alka
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole + amoxicillin with clarithromycin
Study: 15861018
Drug: omeprazole +
Normalized name: Omeprazole + SyrSpend SF Alka
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole + amoxicillin with metronidazole (metronidazole-susceptible bacteria)
Study: 15861018
Drug: omeprazole +
Normalized name: Omeprazole + SyrSpend SF Alka
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole + amoxicillin with metronidazole (metronidazole-resistant bacteria)
Study: 15861018
Drug: omeprazole +
Normalized name: Omeprazole + SyrSpend SF Alka
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole + amoxicillin with clarithromycin (clarithromycin-sensitive strains)
Study: 15861018
Drug: omeprazole +
Normalized name: Omeprazole + SyrSpend SF Alka
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole + amoxicillin with clarithromycin (clarithromycin-resistant strains)
Study: 11967720
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Ang II infusion (A)
Study: 11967720
Drug: Valsartan +
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan + Ang II infusion (VA)
Study: 9464723
Drug: Intravaginal PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal PGE2 gel (2 mg)
Study: 9464723
Drug: Intracervical PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical PGE2 gel (0.5 mg)
Study: 7796228
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin administration for prophylaxis
Study: 7796228
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin administration for treatment
Study: 7008655
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 1 or 2 mg
Study: 31792878
Drug: Morphine drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine drops with ethanol (red morphine drops, RMD)
Study: 31792878
Drug: Morphine drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine drops without ethanol
Study: 26106113
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue-type plasminogen activator (IV r‐tPA)
Study: 21129341
Drug: Continuous glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose monitoring system (CGMS) with low glucose alarm set at 80 mg/dl for 3 days
Study: 15883637
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg daily for 2 years, then 10 mg for 1-2.5 years)
Study: 15603033
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg misoprostol vaginal gel
Study: 15603033
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of prostaglandin E2 gel
Study: 9481721
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous intradialysis rHuEpo therapy
Study: 9481721
Drug: Intravenous postdialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous postdialysis rHuEpo therapy (control)
Study: 791537
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (one or more aortocoronary saphenous vein bypass grafts)
Study: 791537
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (conventional medical treatment)
Study: 31407549
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg TXA administered intravenously before 5-10 minutes of operation (Group A)
Study: 31407549
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg TXA administered intravenously before 5-10 minutes of operation (Group B)
Study: 28697050
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin 7-8 g/dL)
Study: 28697050
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin 10-11 g/dL)
Study: 26673788
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with bevacizumab (BEV) in combination with cytoreductive surgery (CRS) and oxaliplatin-based intraperitoneal chemoperfusion (IPC)
Study: 26673788
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with bevacizumab (BEV)
Study: 23531438
Drug: 2.5mg oral
Normalized name: NALOXEGOL 12.5MG ORAL TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg oral tibolone (n=11)
Study: 23531438
Drug: 1.25mg oral
Normalized name: Glyburide 1.25mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25mg oral tibolone (n=13)
Study: 17719314
Drug: Atorvastatin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (both dosages)
Study: 8250306
Drug: Sufentanil 10
Normalized name: SUFentanil 100 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 10 micrograms plus morphine 250 micrograms
Study: 3114189
Drug: Pion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pion therapy
Study: 10396321
Drug: 5'-DFUR (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-DFUR (800 mg daily for 3 weeks)
Study: 17167280
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment for primary and secondary prevention of CHD
Study: 15519288
Drug: OTC lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OTC lovastatin 20 mg
Study: 9663360
Drug: Domperidone 20
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 20 mg QID for 4 weeks
Study: 3134859
Drug: MQF-OK therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MQF-OK therapy with UFT (group B)
Study: 3134859
Drug: MQF-OK therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MQF-OK therapy with FT (group A)
Study: 15531318
Drug: Radiotherapy (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (20 Gy delivered in 5 daily fractions of 4 Gy each; 6 MV)
Study: 8072721
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists in chronic haemodialysis patients
Study: 8072721
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment in normotensive patients with microalbuminuric diabetes or non-diabetic uraemic nephropathy
Study: 8072721
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors in diabetic nephropathy and non-diabetic uraemic nephropathy
Study: 25135262
Drug: Triamcinolone 0.1%
Normalized name: TRIAMCINOLONE 0.1% CREAM/SILICONE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone 0.1% cream
Study: 18305467
Drug: Cyclosporine with
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine with adjusted dosage to maintain trough levels of 60-80 ng/ml in Group A
Study: 18305467
Drug: Cyclosporine with
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine with fixed dosage of 2.5 mg/kg/day in Group B
Study: 16597078
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (positive control)
Study: 12678512
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 40 mg I.M. with 20 mg chlorpheniramine maleate (CPM)
Study: 12678512
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (CPM, 20 mg) I.M.
Study: 8409568
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin 600 mg tds
Study: 8409568
Drug: Diclofenac dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac dispersible 50 mg tds
Study: 3954112
Drug: Oral controlled
Normalized name: Afeditab CR Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral controlled release morphine (30 mg CRM orally)
Study: 3954112
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (4 mg morphine epidurally)
Study: 26822799
Drug: Creatine augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine augmentation of escitalopram
Study: 26822799
Drug: Placebo augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo augmentation of escitalopram
Study: 25102385
Drug: Activity-based therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity-based therapy (ABT) for 24 weeks, 9h/wk including developmental sequencing, resistance training, repetitive, patterned motor activity, and task-specific locomotor training
Study: 25102385
Drug: Activity-based therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity-based therapy (ABT)
Study: 22485232
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic therapy (control group)
Study: 15083597
Drug: Statin-fibrate combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin-fibrate combination therapy
Study: 15083597
Drug: Statin-niacin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin-niacin combination therapy
Study: 15083597
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of cholesterol ester transfer protein and HDL therapy drugs
Study: 10780713
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) administered orally, twice a day from 36 weeks' gestation until labor and every 3 hours during labor.
Study: 3512944
Drug: Physostigmine 0.004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 0.004 mg/kg
Study: 3512944
Drug: Physostigmine 0.009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 0.009 mg/kg
Study: 3512944
Drug: Physostigmine 0.013
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 0.013 mg/kg
Study: 3512944
Drug: Physostigmine (most
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (most effective dose)
Study: 29071985
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at phenomaxillary ganglia and local acupoints (Yingxiang (LI 20, bilateral) and Yintang (EX-HN 3)) for 20 min, twice per week for 4 weeks.
Study: 29071985
Drug: Oral loratadine
Normalized name: loratadine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loratadine tablets for 4 weeks.
Study: 25344361
Drug: PEB chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEB chemotherapy (cisplatin, etoposide, and bleomycin)
Study: 25344361
Drug: High-dose sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sequential chemotherapy (HDS)
Study: 10730021
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (comprehensive drug therapy management program)
Study: 10730021
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no access to pharmaceutical care)
Study: 1359809
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (initial dose 170 ng.kg‐1 x min‐1, maintenance 10 ng.kg‐1 x min‐1)
Study: 8836267
Drug: Piroxicam gel
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam gel 15gm
Study: 8836267
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic field block with 20 ml of 0.375% bupivacaine
Study: 1349676
Drug: olsalazine (Dipentum;
Approvals — FDA: no, EMA: no, PMDA: no
Description: olsalazine (Dipentum; 1.0 g daily)
Study: 1349676
Drug: mesalazine (Asacol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine (Asacol, with Eudragit‐S coating; 1.2 g daily)
Study: 25688512
Drug: Everolimus in
Normalized name: Product containing everolimus in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus in combination with octreotide LAR and metformin
Study: 19205290
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of fluticasone propionate at 200 microg/d for 4 weeks
Study: 19205290
Drug: Innovator formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovator formulation of fluticasone propionate at 200 microg/d for 4 weeks
Study: 12396273
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg (14)C‐labelled emedastine difumarate (mass balance study)
Study: 12396273
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral emedastine difumarate b.i.d. or 4 mg o.d. for 7 consecutive days (single- and multiple-dose pharmacokinetic study)
Study: 2182581
Drug: TBI/LON (Lonidamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBI/LON (Lonidamine 420 mg/m2 orally daily)
Study: 121884
Drug: Sodium nivimedone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium nivimedone (200 mg thrice daily)
Study: 17101711
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg vitamin K1 intramuscularly (control)
Study: 17101711
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg vitamin K1 intramuscularly
Study: 17101711
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg vitamin K1 intravenously
Study: 17101711
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg vitamin K1 intramuscularly
Study: 15598026
Drug: Timed release
Normalized name: Mega B 100 Timed Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed release glucosamine sulfate (TimeOsamine) 1,000 mg (2 x 500 mg)
Study: 15598026
Drug: Powder-filled glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder-filled glucosamine sulfate formulation 1,500 mg (3 x 500 mg)
Study: 2522729
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 to 100 mg/day)
Study: 11499735
Drug: Not specified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not specified (high-dose angiotensin-converting enzyme inhibitors and beta-blocker therapy)
Study: 9269267
Drug: Copper-salicylate gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper-salicylate gel (1.5 g) applied twice daily for four weeks
Study: 9269267
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (1.5 g) applied twice daily for four weeks
Study: 8387151
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (2 mg E2V and 1 mg CPA)
Study: 8387151
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (1 mg E2V and 0.5 mg CPA)
Study: 8387151
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (2 mg E2V and 2 mg CPA)
Study: 23543732
Drug: Palonosetron (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (75 mcg)
Study: 20459404
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/day, n=48)
Study: 20459404
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n=15)
Study: 16160627
Drug: Tetrahydrobiopterin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrahydrobiopterin (3 mg/kg daily for 6 months)
Study: 11803237
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (120 mg) in severity stratum 1 (MMSE >23)
Study: 11803237
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (120 mg) in severity stratum 2 (MMSE <24)
Study: 11803237
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (120 mg) in patients with very mild to mild cognitive impairment
Study: 11803237
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (120 mg) in patients with more severe dementia
Study: 6175494
Drug: Propafenon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenon (3 x 150 mg daily)
Study: 6175494
Drug: Propranolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (3 x 20 mg daily)
Study: 26132827
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg/kg body mass)
Study: 26821116
Drug: BB-12 capsule
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BB-12 capsule (CAP)
Study: 22763899
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with levobupivacaine 0.375% 20 mL
Study: 22763899
Drug: Sham block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham block with 20 mL 0.9% saline (Control)
Study: 15921806
Drug: Carvedilol (stayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (stayed on the same drug)
Study: 15921806
Drug: Metoprolol (stayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (stayed on the same drug)
Study: 6467282
Drug: Cefazolin 500
Normalized name: cefazolin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 500 mg
Study: 29702283
Drug: Traditional anti-allergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional anti-allergic medications (Control)
Study: 22991405
Drug: Chronic PDE5I
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic PDE5I (sildenafil® 20 mg tid for 12 weeks followed by 60 mg tid for 12 weeks)
Study: 15930452
Drug: Olestra-containing diet
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra-containing diet with daily multivitamin (Centrum)
Study: 8967669
Drug: Accelerated alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accelerated alteplase therapy
Study: 1725890
Drug: Cromakalim 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromakalim 1 mg
Study: 1725890
Drug: Cromakalim 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromakalim 2 mg
Study: 6091484
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g single dose)
Study: 6091484
Drug: Cefazolin (seven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (seven doses)
Study: 29633339
Drug: Intraduodenal acetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal acetic acid infusion (50 mL)
Study: 29633339
Drug: Saline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (50 mL)
Study: 26791556
Drug: Infancy iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infancy iron supplementation (∼1 mg Fe/(kg · d) as oral iron proteinsuccynilate)
Study: 20350920
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment (50 to 100 mcg daily)
Study: 17545843
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 on days 1 and 8, every 21 days for three cycles, followed by Docetaxel 35 mg/m2 on days 1, 8, and 15, every 28 days for three cycles (S0027)
Study: 17545843
Drug: Docetaxel 30
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 30 mg/m2 on days 1, 8, and 15, every 28 days, or 75 mg/m2 every 21 days (LUN 6)
Study: 17524571
Drug: 7 x
Normalized name: TachoSil 3.7 X 1.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 x 5.2 Gy High-Dose-Rate Brachytherapy (HDR-BT)
Study: 11526363
Drug: Sibutramine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 20 mg once daily for 24 weeks
Study: 8322247
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of terbutaline nebuliser solution
Study: 31917054
Drug: Early-stage periarticular
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-stage periarticular injection (injection just before arthrotomy)
Study: 31917054
Drug: Late-stage periarticular
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-stage periarticular injection (placebo before arthrotomy, injection after implantation)
Study: 31160295
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) methotrexate (MTX)
Study: 26079800
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal catheter (3-day ropivacaine 0.2% infusion)
Study: 26079800
Drug: Femoral catheter
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral catheter (3-day ropivacaine 0.2% infusion)
Study: 21121960
Drug: modSLA implants
Normalized name: Mosla cavaleriei whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: modSLA implants
Study: 19216016
Drug: Pentoxifylline, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline, 400 mg twice daily